Developing the right pricing strategy for your product

We use a variety of pricing techniques and approaches to recommend the optimum value-based pricing for your product.

How can we support you:
Payer Insights
Pricing Strategy
BD Commercial Assessments
Tactical Pricing

We can help you

  • Obtain payer and stakeholder insights into the perceived value of your product
  • Identify the optimal price for your product
  • Determine the global pricing strategy
  • Understand payer evidence requirements to support your value-based pricing and reimbursement strategy
  • Conduct commercial assessments for business development assets
  • Implement pricing tactics to optimize post-launch pricing at a list and net price level
Get in touch

Discover the latest insights

Reflecting on the Pricing & Market Access tre…
Our experts reflect on the trends that shaped the European pricing and market access landscape in 20…
Read more
PMA Insights: Week 46 SPECIAL EDITION ISPOR 2022 R…
We summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re…
Read more
ISPOR 2022 Plenary Session 3 – Integrating Data
Our experts provide a detailed summary of Plenary Session 2 at ISPOR 2022 on innovative methods for …
Read more
ISPOR 2022 Plenary Session 1 – HTA and Regulation
Our experts provide a detailed summary of Plenary Session 1 at ISPOR 2022 on the Convergence of HTA …
Read more
PMA Insights: Week 44
We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth …
Read more
A winter of discontent? European pharmaceutical so…
EUCOPE and EFPIA have issued a joint statement expressing concerns regarding the implementation of t…
Read more
PMA Insights: Week 42
We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth …
Read more
UK Agencies join with International HTA Partners f…
A cross-border alliance of health technology assessment (HTA) agencies has been announced by the Can…
Read more
How important is HTA when launching a biosimilar i…
The short answer to the question “how important is HTA when launching a biosimilar in the EU5?” …
Read more
ISPOR 2022: Does NICE’s Sta process effectively …
We investigate Single Technology Appraisals (STAs) conducted by the National Institute for Health an…
Read more

I really enjoyed working with Remap Consulting and received powerful advice. A small company like ours needs to receive a flexible approach in order start with market access activities, and I am very happy to see you are as flexible as possible with us.

Director of Market Access
Small pharma payer insights for clinical trials

Remap Consulting’s pricing knowledge and support has been critical to the success of our new pricing team. Their combined experience has provided them with ‘real-world‘ knowledge that can support their recommendations. I highly recommend Remap Consulting and am delighted to continue my work with their pricing group.

Senior Director, Head of Global Pricing
Outsourcing pricing activities for large biotech

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.